Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Want to see ACXP full AI Analyst Report?
ACXP Stock Chart & Stats
$2.78
-$0.07(-8.37%)
At close: 4:00 PM EST
$2.78
-$0.07(-8.37%)
Day’s Range― - ―
52-Week Range$1.33 - $21.02
Previous CloseN/A
Volume243.54K
Average Volume (3M)1.14M
Market Cap
$7.74M
Enterprise Value-$6.12M
Total Cash (Recent Filing)$9.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.41
Next Earnings
Aug 17, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.91
Shares Outstanding4,297,738
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.80
Forecast
1Y Price Target
$17.00Price Target Upside511.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy (Phase II)Robust Phase II results with ~96% cure and no observed 1-month recurrences among cured patients signal a durable clinical profile that can differentiate ibezapolstat in CDI. Strong early efficacy supports regulatory discussions, informs confirmatory evidence and enhances the likelihood of adoption if replicated in larger trials.
Favorable Regulatory PathwayThe formalized single‑trial plus confirmatory evidence pathway and potential LPAD route materially lower the regulatory bar versus multiple large trials. This structural change can shorten timelines and reduce trial scale/cost, improving the practical feasibility of bringing ibezapolstat through registration for a limited high‑need population.
Intellectual Property & Regulatory DesignationsA broad, multi-jurisdictional patent estate extending toward 2039 combined with QIDP and Fast Track status provides durable competitive protection and regulatory incentives. This mix supports commercialization exclusivity, potential premium positioning against competitors, and incentives that can accelerate development and market entry.
Bears Say
Limited Cash For Phase IIIA $9.3M cash balance is structurally insufficient to fund registrational Phase III studies, creating near-term financing dependency. This increases dilution and execution risk, could delay trial initiation or completion, and forces management to prioritize fundraising over operations and longer-term strategic investments.
Pre-revenue With Ongoing Cash BurnBeing pre-revenue with negative operating and free cash flow means the company cannot self-fund development. Although losses narrowed recently, persistent cash burn necessitates repeated financings, raising dilution risk and creating structural uncertainty around sustained R&D progress absent new capital or partnering.
Small Pilot And Regulatory/design UncertaintyStarting with a 20-patient open-label rCDI pilot limits statistical power and regulatory persuasiveness, requiring larger active-controlled trials afterward. Persistent uncertainties around comparator choice, follow-up duration and FDA alignment elevate cost, timeline and approval risk, affecting long-term program certainty.
Acurx Pharmaceuticals News
ACXP FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was $1.32 and its highest was $21.02 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is $7.74M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Aug 17, 2026 which is in 75 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$1.2 by $0.58.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 4,297,738 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, beating expectations of -$1.2. Following the earnings report the stock price went down -5.963%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in ACXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
ACXP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed materially positive clinical and IP progress: compelling Phase II efficacy with no observed recurrence among cured patients, initiation of an rCDI pilot, favorable FDA guidance that could reduce pivotal trial requirements, strengthened patent protection, supportive preclinical data, and recent financings that improved cash. Key negatives are the modest cash position relative to Phase III needs, small-scale early rCDI data requiring larger controlled trials, and remaining regulatory and design uncertainties. On balance, the positive clinical, regulatory and IP developments outweigh the operational and financing risks disclosed.View all ACXP earnings summariesACXP Stock 12 Month Forecast
Average Price Target
$17.00
▲(511.51% Upside)
Technical Analysis
Ibio
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Bolt Biotherapeutics
―
Ownership Overview
55.41%
Insiders
1.06% Mutual Funds
0.34% Other Institutional Investors
42.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---